Eliaz Therapeutics

Join The Fight Against Sepsis With Our Life-Saving Medical Device: XGal-3®

Print
Claim My Business
Security Type
CAFES
Categories
Technology, Financial Services, Healthcare & Medical
Min Investment
$250
Location
Santa Rosa, , CA
No. Investors
388

Key Deal Facts

Targeting a $62B sepsis treatment market in the USA alone, part of a $1.97T global opportunity
Our technology shuts down the sepsis process within hours in large animal studies
Platform technology with potential applications beyond sepsis, including cancer and kidney disease
Over 60 patents across 34 countries securing our innovative technology
Secured 2 prestigious NIH grants, demonstrating scientific merit and potential for commercialization
Strategic partnership with Terumo BCT for development and commercialization of XGal-3® treatment
Collaboration with a global diagnostics company to support device clinical trials
Addressing critical unmet need: first significant advancement in sepsis treatment in 25 years

Management Team / Advisory Board Bios

Notable Angel
Raised $25k or more from a notable angel investor, Isaac Eliaz CEOPhysician and innovator in conventional and integrative medicine with 30+ years in Galectin-3 research. Founded a high-impact venture acquired by a private equity firm (AUM $22B+), holds 60+ patents, and is driven to create transformative global impact., Anat Stern COO & Biz Dev Over 18 years in healthcare and biotech. Led ecoNugenics for 7 yrs to a successful acquisition. Holds an MBA, BSc, and MSc in Biochemistry, combining scientific expertise and business acumen to drive innovation, growth, and success in complex environment., Milton GossCFOAn accomplished finance executive with more than 20 years of experience in the medical device, life science, and semiconductor industries. Milton has had a particular emphasis on strategy, business modeling, operations, and M&A., Bryan Knipe Investor relations With an MBA and 20+ years of experience in financial management, business development, and M&A, Bryan has scaled ventures across healthcare and medtech. He specializes in securing capital, go-to-market strategies, and fostering relationships for growth., Tom BoomSenior Scientific Advisor- Protein TherapeuticsWith 4 decades in protein therapeutics, including 28 years at Amgen, he grew the Protein Sciences division to over 300 researchers across five locations. He now supports ETI’s R&D efforts and provides expertise in guiding GMP manufacturing., Glenn M Chertow MDDirector of Medical AffairsChief of Nephrology division and a Clinical Research Professor at Stanford School of Medicine and is among the world’s foremost experts in AKI & CKD.
Amount Raised : $600,521
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments